Systemic inflammation and metabolic syndrome in stable COPD patients;Stabil KOAH'lı hastalarda sistemik inflamasyon ve metabolik sendrom

Tuberkuloz ve Toraks

Volumn 60, Issue 3, 2012, Pages 230-237

  Akpinar, Evrim Eylem ^a   Akpinar, Serdar ^b   Ertek, Sibel ^a   Sayin, Esen ^a   Gülhan, Meral ^a  

^a UFUK UNIVERSITY   (Turkey)

^b Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital Ankara   (Turkey)

Author keywords

COPD; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN;

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; GROUPS BY AGE AND SEX; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PROTEIN BLOOD LEVEL; RATING SCALE; STATISTICAL SIGNIFICANCE; THE NATIONAL CHOLESTEROL EDUCATION PROGRAMS ADULT TREATMENT PANEL 3; VENOUS BLOOD;

EID: 84867169456     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: 10.5578/tt.4018     Document Type: Article

References (37)

1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Updated 2008. Available from: http://www.goldcopd.org/
2. Fabbri LM, Rabe K. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-99.
3. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of co morbidities. Eur Respir J 2006; 28: 1245-57.
4. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-9.
5. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-80.
6. Magnussen H, Watz H. Systemic inflammation in chronic obstructive pulmonary disease and asthma: relation with co morbidities. Proc Am Thorac Soc 2009; 6: 648-51.
7. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
8. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41: 715-22.
9. Watz H, Waschki B, Kirsten A, Müler KC, Kretschmar G, Meyer T, et al. The metabolic syndrome in patients with chronic bronchitis and COPD. Chest 2009; 136: 1039-46.
10. Lam KB, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010; 35: 317-23.
11. Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord 2004; 2: 82-204.
12. Marquis K, Maltais F, Duguay V, Bezeau AM, LeBlanc P, Jobin J, et al. Metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005; 25: 226-32.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
14. Bolton CE, Evans M, Ionescu A, Edwards SM, Morris RH, Luzio S, et al. İnsulin resistance and inflammation-a further systemic complication of COPD. COPD 2007; 4: 121-6.
15. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure determination by sphygmomanometer. Circulation 1993; 88: 2460-70.
16. Lohmann T, Roche ARM. The Airlie (VA) consensus: standardization of anthropometric measurements. Human Kinetic Publishers, Champaign IL, 1988: 39-80.
17. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. For the Conference Participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-8.
18. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011; 139: 165-73.
19. Barnes PJ, Celli BR. Systemic manifestations and co morbidities of COPD. Eur Respir J 2009; 33: 1165-85.
20. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic co morbidities of COPD. Eur Respir J 2008; 31: 204-12.
21. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-80.
22. Hurst JR, Vestbo J, Anzueto Locantore N, Müllerova H, Tal-Singer R, Miller B, et al. for the ECLIPSE Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
23. De Torres JP, Pinto-Plata V, Casanova C. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 1333: 1336-43.
24. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-5.
25. Stanciu S, Marinescu R, Iordache M, Dumitrescu S, Mureşan M, Boǧdan MA. Are systemic inflammatory profiles different in patients with COPD and metabolic syndrome as compared to those with COPD alone? Rom J Intern Med 2009; 47: 381-6.
26. Sanisoǧlu SY, Oktenli C, Hasimi A, Yokusoǧlu M. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006; 6: 92. doi:10.1186/1471-2458-6-92
27. Gemalmaz A, Aydi{dotless}n S, Başak O, Disçigil G, Korul A. Prevalence of the metabolic syndrome in a rural Turkish population: comparison and concordance of two diagnostic criteria. Turk J Med Sci 2008; 38: 159-65.
28. Gündoǧan K, Bayram F, Capak M, Tanri{dotless}verdi F, Karaman A, Ozturk A, et al. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab Syndr Relat Disord 2009; 7: 427-34.
29. Barr RG, Celli BR, Mannino DM. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-55.
30. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-9.
31. Poulain M, Doucet M, Drapeau V, Fournier G, Tremblay A, Poirier P, et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chronic Respiratory Disease 2008; 5: 34-41.
32. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008; 31: 741-6.
33. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006; 7: 109-16.
34. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
35. Karadaǧ F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008; 19: 104-8.
36. Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
37. Gläser S, Ittermann T, Koch B, Völzke H, Wallaschofski H, Nauck M, et al. Airflow limitation, lung volumes and systemic inflammation in a general population. Eur Respir J 2012; 39: 29-37.